The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice 70k buy just reported causing today's tick up
Our team will be attending the Bio-Europe in Berlin on the 6-8th November. http://www.vennlifesciences.com/meet-team-bio-europe/
weedavemac , ye i get that , but some positive news could really move this north. 22p was a solid base before we had the seller.
Personally quite happy with a slow and steady rise....
rivaldo , could do with some news to get this thing moving.
....and a �5,700 buy has just caused another 0.375p jump, so stock is presumably still hard to find.
Two buys today - and the price has moved up on each one even though they only total �1,600 :o)) Looks like the stock shortage is continuing.
A 50k buy at 13.8p has moved the price forward nicely this morning.
Just moved up another 0.38p on a single �1,400 buy :o)) Could be quite a dramatic rise in store if there's now such a shortage of stock. There were barely any shares available to buy online around lunchtime.
I think right here is the point at which it has to decide.
Delayed buy trades to be reported later? Nice 155k buy @ 13.25p was sneakily posted last week after the bell.
I bought some too, not showing on here or moneyam, seems to have ticked up afterwards good sign
Very good value at that price. The buyer will do well medium/long term
Nice 100,000 buy just now at 12.95p, almost the full 13p offer price.
with a VENN operations manager re their clinical trial expertise: Https://www.med-technews.com/features/tried-and-tested-venn-life-sciences-clinical-trials/ Extracts: "Q&A: talking investigator initiated trials with Venn Life Sciences by Dave Gray 28 September 2017 Behind every great medical device, there�s a great clinical trial. MTI editor Dave Gray spoke to Colette Donaghy, clinical operations manager, Venn Life Sciences, to find out what goes into making a device trial successful." "....Donaghy says that Venn continues to attract innovators from around the globe. In fact, the group recently collaborated in a clinical trial in cardiology which turned out to be one of the largest investigator-lead studies in disease of the left main artery being conducted anywhere in the world. The project began when Venn�s COO was approached by one of two lead investigators, Professor Robert-jan van Geuns at the Erasmus University in the Netherlands. Both he and Professor Keith Oldroyd who is based in the Golden Jubilee Hospital in Glasgow realised at a very early stage that they needed help to conduct this large-scale investigator initiated study.... .....The first challenge was the administrative task of setting up the study in different countries. To do that requires knowledge of the regulatory pathways in each country. Venn has experts around the world capable of undertaking this kind of work. Donaghy says that this specialist knowledge is invaluable when trying to conduct trials on an international scale. �In each country we had to go through the relevant ethical review bodies, who looked at the study, checked that they were happy for it to be conducted, and that there would be no negative impact for the patient.� The other challenge for the client was setting up contracts. Venn needed to set up a contract with each institution, and in some cases with each investigator..... �There�s a lot to do when setting up an international clinical trial. Each country needs to be set up individually and the sites trained in the study processes. And if that�s going to be happening in different countries, then you need people who can speak the language.� Venn has sites in Russia, Poland, Germany, France, the Netherlands and the UK. The trial is ongoing, and Donaghy says that there is significant interest from clinicians in the eventual findings and the primary outcomes at 24 months. �This study will be followed up for the next five years. We will monitor major adverse coronary events and they�ll be classed into categories � e.g. bleeding, thrombosis, stent replacement, etc. We will monitor this over a period of five years, allowing us to look back and see why those things happened. �Currently the client is highly satisfied that we delivered the trial within the timelines that we were given, and that we managed to get full re
A 100,000 buy at 12.41p has caused a tick up. I note this morning's acquisition by Ergomed of PSR, "an international niche contract research organisation". They're paying �5.7m for a business with �4.7m of annual revenues and �0.34m EBITDA. VENN are forecast to make �18.5m revenues this year, with �0.9m EBITDA. On a PSR basis, this would value VENN at around �22.5m. On an EBITDA basis this would value VENN at around �15m. This compares to VENN's current m/cap of �8.6m.
I am confident that our time will come, but it is so hard to leave money invested here when there is so little currently happening in terms of volume or SP, meanwhile other AIM shares are the current darlings and getting all the love and attention. This is defo a slow burner.
Davy Stockbrokers have produced a new note on VENN - client-only, but the intro sounds positive enough: Https://www.davy.ie/research/public/article.htm?id=ST2_1817_1.xml.htm "Venn Life Sciences H1 results: Solid revenues; building on its operational capability Sep 12 2017, 08:00 IST/BST Company Report 5 page(s) Sectors: Pharma and healthcare COMPANIES: Venn Life Sciences DAVY VIEW Venn’s interim result reflects a business in the growth phase of its development. Infrastructure and systems initiatives are being implemented to improve profitability. The management team was further strengthened with the appointment of a new COO. H1 revenues and EBITDA were adversely affected by the deferral of a late phase project to Q1 2018, which needs to be reflected in our full-year forecasts. With significant scope to increase margins in a growing sub-segment of the healthcare market, we remain confident on Venn’s long-term prospects."
I for one will be extremely happy for the directors if the share price exceeds the 45p required for full vesting of the options issued to them yesterday: "The options vest in three equal instalments when the Company's share price trades at 25p, 35p and 45p for twenty consecutive days." Most options are exercisable either at the current share price or, in some cases, with no exercise price at all - pure profit. These VENN's options strike me as rather shareholder-friendly. And also an indication that perhaps the bottom has been reached.
My prior post stated I didn't think VENN would achieve Hybridan's forecasts this year - I reckoned on a €600k PBT rather than Hybridan's €1.27m PBT. Well whaddyaknow - Hybridan's new forecast is €0.77m PBT, with €0.9m EBITDA. So I wasn't too far off :o)) They "understand that the pipeline remains strong and should significant deals land in Q3 or early Q4 there remains the possibility of upgrades." VENN have: - €2.9m of cash (forecast to rise to €3.1m at the year end) - £1.25m of shares in Integumen PLC - trade on an EV/EBITDA of only 6, with sector deals being struck between 13 and 25 - should have €18.5m of revenues this year - now more realistically forecast to make €0.77m PBT this year Pretty good against a mere £7.5m m/cap.
Hi Adj In answer to your queries there are a couple of rns in relation to the acquisition of Kinesis on pg2 of the rns's here, but the original proposal is in the rs dated 22/9/15. Re not lowering the buy price here, can buy for 12.4 and sell (not many) at 12.04, seems fair ? I thought you had were out of funds to buy here ?
Why would you not lower the buy price here? Seems games maybe afoot (don't hv L2) ? Anyone any ideas. Also anyone responding when they say there is no further consideration on the purchase of this new company, which RNS describes the deal?
This is where I had intended to start buying. A) I hv no money. B) No one is rushing to buy. The RSI is still well above 30 so not oversold. I think if people start to buy others will take it up and that 12.5 will be the low but if it does not recover sufficiently today then it would seem it will slip further down until the RSI is below well below 30 pity I think this is a nice little company always have done
apologies, 13.63ers
you & me getting fleeced today it seems, I had already sold the 14.63's I bought for a small profit the other day but holding more above unfortunately, I'll be buying them back but not just yet